These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14501797)

  • 1. Microbicides and HIV: help or hindrance?
    Karmon E; Potts M; Getz WM
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):71-5. PubMed ID: 14501797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shifts in condom use following microbicide introduction: should we be concerned?
    Foss AM; Vickerman PT; Heise L; Watts CH
    AIDS; 2003 May; 17(8):1227-37. PubMed ID: 12819525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers.
    Smith RJ; Bodine EN; Wilson DP; Blower SM
    AIDS; 2005 Mar; 19(4):413-21. PubMed ID: 15750395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of microbicides and changes in condom usage on HIV prevalence in men and women.
    Chen FH
    AIDS; 2006 Jul; 20(11):1551-3. PubMed ID: 16847411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.
    Gafos M; Mzimela MA; Ndlovu HB; McCormack S; McGrath N
    AIDS Care; 2013; 25(5):573-8. PubMed ID: 22971053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city.
    Peitzmeier SM; Tomko C; Wingo E; Sawyer A; Sherman SG; Glass N; Beyrer C; Decker MR
    AIDS Care; 2017 Nov; 29(11):1453-1457. PubMed ID: 28271718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Communicating about microbicides with women in mind: tailoring messages for specific audiences.
    Sidibe S; Pack AP; Tolley EE; Ryan E; Mackenzie C; Bockh E; Githuka G
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19151. PubMed ID: 25224612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much could a microbicide's sexually transmitted infection efficacy contribute to reducing HIV risk and the level of condom use needed to lower risk? Model estimates.
    Foss AM; Vickerman PT; Alary M; Watts CH
    Sex Transm Infect; 2009 Aug; 85(4):276-82. PubMed ID: 19208696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners.
    McMahon JM; Morrow KM; Weeks M; Morrison-Beedy D; Coyle A
    J Assoc Nurses AIDS Care; 2011; 22(1):9-16. PubMed ID: 21211700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo models of HIV sexual transmission and microbicide development.
    Ariën KK; Kyongo JK; Vanham G
    Curr HIV Res; 2012 Jan; 10(1):73-8. PubMed ID: 22264048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current State of Microbicide Development.
    Traore YL; Chen Y; Ho EA
    Clin Pharmacol Ther; 2018 Dec; 104(6):1074-1081. PubMed ID: 30107032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Willingness of clinicians to integrate microbicides into HIV prevention practices in southern Africa.
    Harper CC; Holt K; Nhemachena T; Chipato T; Ramjee G; Stratton L; Blum M; McCulloch CE; Mgweba S; Blanchard K
    AIDS Behav; 2012 Oct; 16(7):1821-9. PubMed ID: 22210482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage and flow: intimate experiences of condoms and microbicides in a South African clinical trial.
    Stadler J; Saethre E
    Cult Health Sex; 2011 Jan; 13(1):31-44. PubMed ID: 20960355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thinking about vaginal microbicide testing.
    Potts M
    Am J Public Health; 2000 Feb; 90(2):188-90. PubMed ID: 10667178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women's interest in vaginal microbicides.
    Darroch JE; Frost JJ
    Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising microbicide approach for prevention of human immunodeficiency virus transmission needs more support.
    Idemyor V
    Pharmacotherapy; 2002 Aug; 22(8):1074-6. PubMed ID: 12173795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
    das Neves J; Amiji M; Sarmento B
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):389-99. PubMed ID: 21506290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties.
    Morrow KM; Fava JL; Rosen RK; Vargas S; Barroso C; Christensen AL; Woodsong C; Severy L
    J Acquir Immune Defic Syndr; 2007 May; 45(1):93-101. PubMed ID: 17325607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in condom use among homosexual men in San Francisco.
    Catania JA; Coates TJ; Stall R; Bye L; Kegeles SM; Capell F; Henne J; McKusick L; Morin S; Turner H
    Health Psychol; 1991; 10(3):190-9. PubMed ID: 1879391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.